This disclosure features
clusterin (CLU) as a multifunctional biotherapeutic for promoting ocular nerve regeneration for various ocular conditions. This disclosure features methods of using CLU for treating a subject with an ocular disorder, condition, or
disease (e.g., an
ocular surface disease,
corneal disease or
retinal disease). The methods described herein can be used for the treatment of ocular inflammatory conditions involving barrier disruption and nerve loss due to its ability to protect and promote the regeneration of ocular nerves.